drugset / Trial / NCT05466175
A Study of Olverembatinib in the Treatment of Ph+ ALL
NaSingle-groupOpen-labelTreatment
Summary
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of a novel third-generation TKI Olverembatinib. The main purpose of the study is to evaluate the efficacy and safety of Olverembatinib in Ph+ ALL patients.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2023-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olverembatinib | Small molecule | 40 mg | Oral |
| Background | Prednisone | Other / unclassified | — | Intravenous |
| Background | Vincristine | Small molecule | — | Intravenous |